Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Union Bancaire Privee UBP SA

Union Bancaire Privee UBP SA decreased its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 5.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 741,433 shares of the company’s stock after selling 44,839 shares during the period. Union Bancaire Privee UBP SA’s holdings in Teva Pharmaceutical Industries were worth $20,606,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of TEVA. Aster Capital Management DIFC Ltd purchased a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at approximately $25,000. Allworth Financial LP increased its holdings in Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after acquiring an additional 329 shares in the last quarter. Grove Bank & Trust raised its position in shares of Teva Pharmaceutical Industries by 300.0% during the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after purchasing an additional 750 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Teva Pharmaceutical Industries by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after acquiring an additional 345 shares in the last quarter. Finally, Global Retirement Partners LLC boosted its stake in shares of Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after purchasing an additional 292 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, insider Mark Sabag sold 144,180 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the completion of the transaction, the insider owned 80,760 shares of the company’s stock, valued at approximately $2,825,792.40. The trade was a 64.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Amir Weiss sold 10,679 shares of the firm’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total value of $384,444.00. Following the completion of the transaction, the chief accounting officer directly owned 20,016 shares of the company’s stock, valued at approximately $720,576. This trade represents a 34.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 465,931 shares of company stock worth $16,332,989 in the last quarter. 0.54% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

TEVA has been the subject of a number of recent analyst reports. Wall Street Zen raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, April 20th. Piper Sandler reaffirmed an “overweight” rating and set a $42.00 target price (up from $41.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, April 30th. Barclays raised their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Finally, Bank of America increased their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 9th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and an average price target of $41.78.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA opened at $33.24 on Friday. Teva Pharmaceutical Industries Ltd. has a 12 month low of $14.99 and a 12 month high of $37.35. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The company’s 50 day simple moving average is $33.73 and its 200 day simple moving average is $32.39. The firm has a market capitalization of $38.22 billion, a PE ratio of 24.99, a P/E/G ratio of 4.11 and a beta of 0.84.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. The firm had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. As a group, equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.97 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.